negative regulation of dendrite development
Definition
Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate or extent of dendrite development. [GOC:obol]
Negative regulation of dendrite development is a complex biological process that involves a precise interplay of molecular signaling pathways, transcription factors, and cytoskeletal dynamics. Dendrites, the branched extensions of neurons, are crucial for receiving and integrating synaptic inputs, and their proper development is essential for neuronal function and circuit formation. The negative regulation of dendrite development ensures that dendrites are not excessively branched or elongated, maintaining an appropriate balance for optimal synaptic integration and neuronal communication. This process involves a diverse array of molecular mechanisms, including:
- **Inhibition of signaling pathways:** Specific signaling pathways, such as the Wnt, Notch, and Ephrin pathways, are known to promote dendrite growth and branching. Negative regulation can occur by inhibiting the activation of these pathways through the expression of specific inhibitors or by sequestering downstream effectors.
- **Regulation of transcription factors:** Transcription factors, like MeCP2 and REST, play a crucial role in controlling the expression of genes involved in dendrite development. Negative regulation can involve the repression of these transcription factors, preventing the transcription of genes required for dendrite growth.
- **Control of cytoskeletal dynamics:** The cytoskeleton, composed of microtubules and actin filaments, provides the structural framework for dendrite formation and growth. Negative regulators can affect the dynamics of these cytoskeletal components, limiting their assembly and promoting their disassembly, thereby restricting dendrite extension.
- **Microtubule-associated proteins:** Proteins like MAP2 and Tau, which are associated with microtubules, are critical for dendrite stability and growth. Negative regulators can influence the phosphorylation state or binding properties of these proteins, leading to reduced dendrite growth and branching.
- **Synaptic activity:** The level of synaptic activity can also influence dendrite development. Negative regulation can involve the suppression of synaptic activity, which in turn inhibits the downstream signaling pathways required for dendrite growth.
- **Cell-cell interactions:** Interactions between neurons, including their axons and dendrites, are crucial for dendrite development. Negative regulators can influence these interactions by affecting adhesion molecules or secreted factors, ultimately limiting dendrite growth and branching.
In summary, negative regulation of dendrite development is a multi-faceted process involving the interplay of various molecular mechanisms, all working together to fine-tune dendrite morphology and ensure proper neuronal function.'
"
Proteins (1)
| Protein | Definition | Taxonomy |
|---|---|---|
| Histone-arginine methyltransferase CARM1 | A histone-arginine methyltransferase CARM1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q86X55] | Homo sapiens (human) |
Compounds (4)
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| furamidine | furamidine: RN given refers to parent cpd; WR 199385 refers to di-HCl; pafuramidine is a prodrug of this | ||
| s-adenosylhomocysteine | S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine. S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. | adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide | cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite |
| stilbamidine | stilbamidine: RN given refers to parent cpd | ||
| gsk343 | GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM). GSK343: an EZH2 methyltransferase inhibitor | aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide | antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor |